alpha-aminopyridine has been researched along with Minimal Disease, Residual in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajciova, V; Jezova, M; Kanderova, V; Krenova, Z; Kyr, M; Lakka Klement, G; Merta, T; Mudry, P; Noskova, K; Palova, H; Pokorna, P; Slaby, O; Sterba, J; Valik, D; Vasikova, A; Zdrazilova Dubska, L | 1 |
| Estey, EH; Percival, MM | 1 |
1 review(s) available for alpha-aminopyridine and Minimal Disease, Residual
| Article | Year |
|---|---|
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
1 other study(ies) available for alpha-aminopyridine and Minimal Disease, Residual
| Article | Year |
|---|---|
Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.
Topics: Aminopyridines; Humans; Lactams; Lactams, Macrocyclic; Lymphoma, Large-Cell, Anaplastic; Neoplasm, Residual; Pyrazoles | 2022 |